drugset / Trial / NCT01190462

Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT01190462

Phase 2 Unknown 51 enrolled Leiden University Medical Center
Open-labelTreatment

Summary

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Simvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Simvastatin may help cetuximab work better by making tumor cells more sensitive to cetuximab. Giving cetuximab together with simvastatin may kill more tumor cells. PURPOSE: This phase II trial is studying giving cetuximab together with simvastatin in treating patients with advanced or metastatic colorectal cancer.

Timeline

Start
2010-08
Primary completion
2012-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody Intravenous
Subject Simvastatin Small molecule Oral

Indications